Krystal Biotech, Inc.

NASDAQ:KRYS

Biotechnology

Healthcare
$315.34 +5.66%

+$18.29 today

Market cap
$9.34B
Beta
0.53
P/E (TTM)
44.5
EPS (TTM)
$7.68
52W Low $130.17High $347.67

Volume 0.35M

Average 0.29M

KRYS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Krystal Biotech, Inc.NASDAQ: KRYS

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $14.16M rose 0.3% year over year, ahead of the -23.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at +17.9% a year.

Context

  • Stock-based compensation amounted to 14.0% of revenue in FY2025, down 2.9 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.3% holds above the trailing-twelve-month pace of -23.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$14.16M+4.0% QoQ
Last fiscal yearDec 2025
$54.51M+11.0% YoY
LTMJun 2026
$41.53M-23.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.3%——
1 year+11.0%——
3-year CAGR+17.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
54.51M USD
Year-over-year change
+11.0%
4-year CAGR
+37.3%

Stock-Based Compensation vs competitors

How KRYS compares with its peers on the latest reported figures

  • KRYS's LTM Jun 2026 stock-based compensation of $41.53M is the 2nd largest of the 6 companies compared; the peer median is $34.64M.
  • Its year-over-year change of -23.5% is the 5th highest of 6, against a peer median of -7.4%.
  • Stock-based compensation amounts to 9.4% of revenue for KRYS, versus a peer median of 57.3%.
KRYS Competitors Peer median
Stock-Based Compensation for KRYS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGTXMeiraGTx Holdings plcLTM Mar 2026$47.93M +107.3%-8.3%60.1%
KRYSKrystal Biotech, Inc.LTM Jun 2026$41.53M -23.5%+17.9%9.4%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$35.22M -20.0%+6.1%—
RGNXREGENXBIO Inc.LTM Mar 2026$34.64M -7.4%-5.4%39.4%
SANASana Biotechnology, Inc.LTM Mar 2026$24.1M -32.3%-12.7%—
ABEOAbeona Therapeutics Inc.LTM Mar 2026$8.33M +7.1%+52.3%57.3%
Peer median (excluding KRYS) $34.64M-7.4%-5.4%57.3%

Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(69.57M)(139.98M)10.93M89.16M204.83M
Depreciation & Amortization2.77M4.05M5.01M6.71M6.55M
Deferred Income Tax0000(22.85M)
Stock-Based Compensation15.32M33.23M39.93M49.13M54.51M
Change in Working Capital2.05M2.81M(37.88M)(14.46M)(36.42M)
Accounts Receivables00(42.04M)(62.71M)(22.12M)
Inventory00(4.48M)(11.91M)(6.29M)
Accounts Payables712K(1.25M)(101K)1.01M826K
Other Working Capital1.34M4.07M8.73M59.15M(8.84M)
Other Non-Cash Items1.49M(690K)(106.79M)(7.12M)(5.77M)
Operating Cash Flow(47.94M)(100.57M)(88.8M)123.42M200.87M
Capital Expenditures(68.34M)(52.98M)(11.8M)(4.24M)(11.95M)
Acquisitions (Net)0000435K
Purchases of Investments(190.46M)(318.78M)(508.78M)(457.74M)(422.54M)
Sales of Investments32.03M257.68M503.21M298.54M375.64M
Other Investing Activities00100M00
Investing Cash Flow(226.77M)(114.08M)82.64M(163.44M)(58.42M)
Debt Repayment00000
Common Stock Issued355.65M36M203.5M32.4M22.66M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(7.96M)(649K)(749K)(5.39M)(13.96M)
Financing Cash Flow347.69M35.35M202.75M27.01M8.71M
Effect of Forex Changes0(41K)(156K)(458K)286K
Net Change in Cash72.98M(179.35M)196.43M(13.46M)151.44M
Free Cash Flow(116.27M)(153.55M)(100.6M)119.18M188.91M

Krystal Biotech, Inc.

NASDAQ:KRYS

Intrinsic Alpha fair value

Locked

Current Price

$315.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.